WallStreetZenWallStreetZen

NASDAQ: BOLD
Boundless Bio Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their BOLD stock forecasts and price targets.

Forecast return on equity

Is BOLD forecast to generate an efficient return?

Company
N/A
Industry
68.21%
Market
181.01%

Forecast return on assets

Is BOLD forecast to generate an efficient return on assets?

Company
N/A
Industry
31.86%

BOLD earnings per share forecast

What is BOLD's earnings per share in the next 2 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$2.15
Avg 2 year Forecast
-$1.05

BOLD revenue forecast

What is BOLD's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

BOLD vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BOLD$1.19N/AN/A
HYPD$3.27$5.88+79.66%Strong Buy
SER$2.54N/AN/A
CUE$0.27N/AN/A
BRNS$0.63$4.00+534.92%Buy
View Top Biotech Stocks

Boundless Bio Stock Forecast FAQ

What is BOLD's earnings growth forecast for 2026-2027?

(NASDAQ: BOLD) Boundless Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.93%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.08%.

Boundless Bio's earnings in 2026 is -$58,197,000.On average, 5 Wall Street analysts forecast BOLD's earnings for 2026 to be -$48,072,516, with the lowest BOLD earnings forecast at -$55,117,356, and the highest BOLD earnings forecast at -$42,584,981.

In 2027, BOLD is forecast to generate -$23,464,873 in earnings, with the lowest earnings forecast at -$27,668,474 and the highest earnings forecast at -$17,175,158.

If you're new to stock investing, here's how to buy Boundless Bio stock.

What is BOLD's revenue growth forecast for 2026-2028?

(NASDAQ: BOLD) Boundless Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.63%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.32%.

Boundless Bio's revenue in 2026 is $0.On average, 5 Wall Street analysts forecast BOLD's revenue for 2026 to be $0, with the lowest BOLD revenue forecast at $0, and the highest BOLD revenue forecast at $0. On average, 5 Wall Street analysts forecast BOLD's revenue for 2027 to be $0, with the lowest BOLD revenue forecast at $0, and the highest BOLD revenue forecast at $0.

In 2028, BOLD is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is BOLD's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: BOLD) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 31.86%.

What is BOLD's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: BOLD) Boundless Bio's current Earnings Per Share (EPS) is -$2.60. On average, analysts forecast that BOLD's EPS will be -$2.15 for 2026, with the lowest EPS forecast at -$2.46, and the highest EPS forecast at -$1.90. In 2027, BOLD's EPS is forecast to hit -$1.05 (min: -$1.23, max: -$0.77).

What is BOLD's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: BOLD) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.